Equine protozoal myeloencephalitis
Equine protozoal myeloencephalitis (EPM), is a disease caused by the apicomplexan parasite "Sarcocystis neurona" that affects the central nervous system of horses. History. EPM was first discovered in the 1960s by the American biologist Dr. Jim Rooney. The disease is considered rare, though recently, an increasing number of cases have been reported. Previous research identified the "barn cat" as the definitive host of the disease. However, since that time it has been learned that the definitive host is the opossum, while any of a number of mammals can serve as intermediate hosts in the disease's two -host life-cycle. Those with horses should not panic and kill opossums or wildlife rather keep feed covered and stalls clean. The term EPM refers to the clinical neurologic symptoms caused by the parasite, not infection itself. The majority of horses infected with "S. neurona" do not exhibit neurologic symptoms consistent with EPM. There are six subspecies of "S. neurona" which can be identified by surface antigens (SAG). Equine EPM is caused by the parasites that exhibit SAG1, SAG5, and SAG6. SAG1 and SAG5 are responsible for the majority of EPM cases in horses. Horses produce antibodies to these surface  antigens. Serum antibody testing is available that measures levels of these antibodies in the blood of horses, which is helpful in diagnosing EPM in an ataxic horse. Serial blood levels are helpful in guiding treatment. In experimentally infected horses it takes 14 days from infection to positive antibody tests. 80% of horses with EPM have positive antibody tests. A negative antibody test in the presence of EPM results if testing is done before 17 days or if the horse has been treated with antiprotozoal drugs which delays antibody production. Causes. EPM is caused by the parasite "Sarcocystis neurona. "The life  cycle of "S. neurona" is well described. In order to complete its life cycle this parasite needs two hosts, a definitive and an intermediate. In the laboratory, raccoons, cats, armadillos, skunks, and sea otters have been shown to be intermediate hosts. The opossum is the definitive host of the disease, passing the parasite through feces. Horses contract EPM from contaminated feed or water. Horses cannot pass the disease among themselves; that is, one horse cannot contract the disease from another infected horse. The horse is a dead-end, or aberrant, host of the parasite. Symptoms. The most common  symptoms of EPM are ataxia, general weakness with muscle spasticity. However this is not specific to EPM and is common to many other neurological disorders. Clinical signs among horses with EPM include a wide array of symptoms that may result from primary or secondary problems. Some of the signs are difficult to distinguish from other problems, such as lameness, which can be attributed to many different causes. Apparent lameness, particularly atypical lameness or slight gait asymmetry of the rear limbs are commonly caused by EPM. Focal muscle atrophy, or even generalized muscle atrophy or loss of condition may result. Secondary  signs also occur with neurologic disease. Airway abnormalities, such as laryngeal hemiplegia, snoring, or airway noise of undetermined origin may result from damage to the nerves which control the throat, although this is quite uncommon. In experimentally infected horses, very early signs included loss of appetite, decreased tongue tone, facial paresis, altered mental status, generalized weakness, and lameness. It is thought that "Sarcocystis neurona" does not need to enter the CNS to cause disease, in some cases "S. neurona" has been found in the CNS but usually not. In cases where "S. neurona" is found in the CNS, white blood  cells probably play a role in the parasite's penetration of the blood brain barrier. Treatment and prevention. EPM is treatable, but irreversible damage to the nervous system is possible. It is important to identify the disease as early as possible and begin treatment with antiprotozoal drugs. There are currently three FDA approved treatments available in the US: ReBalance (sulfadiazine and pyrimethamine), Marquis (ponazuril), and Protazil (diclazuril). These drugs minimize the infection but do not kill the parasite. The use of anti-inflammatory agents such as Banamine, corticosteroids, or phenylbutazone are often used to help reduce inflammation and limit further  damage to the CNS. Antioxidants, such as vitamin E may help promote the restoration of nervous tissue. Response to treatment is often variable, and treatment may be expensive. Recently, antiprotozoal treatments that kill the parasite and clear the infection have shown promise. The inflammatory component is thought responsible for the symptoms of EPM; anti inflammatory drugs that target the IL-6 pathway have been particularly effective at reversing symptoms. Control of this disease includes proper storage of hay and feed, the control of "barn cats" on the property, and prompt disposal of animal carcasses. No vaccine is available. Equine protozoal myeloencephalitis